Trump Administration Halts New Medical Equipment Suppliers Amid Fraud Concerns

The Trump administration has paused the approval of new suppliers for durable medical equipment (DME) nationwide, a move intended to curb what officials describe as widespread fraud, waste, and abuse within the industry. The policy, announced Wednesday, affects companies providing items like wheelchairs, oxygen tanks, and prosthetics, impacting access to essential medical supplies for seniors and individuals with disabilities.

Centers for Medicare & Medicaid Services (CMS) Administrator Mehmet Oz, speaking alongside Health Secretary Robert F. Kennedy, Jr. And Vice President JD Vance, emphasized the scale of the problem. “The amount of fraud is so massive that it’s easier to open one of these suppliers than to open a bank account,” he stated during a press conference focused on tackling healthcare fraud. This action signals a renewed focus on financial integrity within the DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics, and Supplies) sector.

A History of Fraud and Improper Payments

The decision to implement a moratorium stems from an analysis of Medicare enrollment and claims data, as detailed in a Federal Register notice. While DMEPOS suppliers represent a relatively small fraction – a “miniscule portion” – of CMS’s $1.7 trillion budget, the industry has consistently faced scrutiny for fraudulent activity. Past investigations have revealed significant improper payments. Between 2015 and 2017, Medicare improperly paid suppliers $34 million for equipment provided during inpatient stays. More recently, between 2018 and 2024, improper payments totaled $22.7 million.

This isn’t the first time CMS has utilized moratoriums to address fraud. Similar pauses have been implemented in the past for home health agencies and ambulance suppliers, demonstrating a pattern of using this tool to investigate and rectify systemic issues. The current moratorium is slated to last for six months, with the possibility of six-month extensions permitted under federal law (42 CFR §424.570).

What Does This Signify for Patients?

The pause on new supplier approvals is not intended to disrupt the existing supply of durable medical equipment. Patients who currently receive equipment from established suppliers should continue to do so without interruption. The affected equipment includes essential items such as gauze, oxygen tanks, urinary catheters, and breast prostheses for individuals who have undergone mastectomies. However, individuals who were planning to establish new DME supply relationships may experience delays.

Josh Marx, CEO of the Medical Service Company and chairman of the board for AAHomecare, acknowledged the commitment to preventing fraudulent enrollment. “We appreciate CMS Administrator Oz’s demonstrated commitment to preventing criminals from enrolling in the DMEPOS program,” he said. AAHomecare, which represents providers and manufacturers, hopes to collaborate with CMS to strengthen enrollment practices without hindering patient access to necessary equipment and services.

Beyond DMEPOS: Broader Crackdown on Healthcare Fraud

The announcement of the DMEPOS moratorium was accompanied by additional measures aimed at combating healthcare fraud. Federal health department leaders also revealed plans for a new CMS tipline dedicated to reporting fraudulent activity. Simultaneously, a “temporary halt” on $259.5 million in Medicaid funding to Minnesota was announced, signaling a broader, nationwide effort to address financial irregularities within healthcare programs. This separate action, while distinct from the DMEPOS moratorium, underscores the administration’s commitment to fiscal responsibility and program integrity.

Understanding Durable Medical Equipment and its Role in Healthcare

Durable medical equipment encompasses a wide range of medical supplies and devices intended for long-term leverage. These items are typically prescribed by a physician and are considered medically necessary for individuals with chronic conditions or disabilities. The DMEPOS sector plays a critical role in enabling patients to manage their health conditions at home, reducing the need for costly hospitalizations and institutional care. However, the complexity of billing and reimbursement processes, coupled with the potential for fraudulent schemes, has made this sector particularly vulnerable to abuse.

What’s Next for CMS and the DMEPOS Sector?

While CMS Administrator Oz did not specify concrete targets for the six-month pause, the agency is expected to use this time to review and strengthen its enrollment procedures for DMEPOS suppliers. This may involve enhanced background checks, more rigorous vetting of applicants, and improved data analytics to identify and prevent fraudulent activity. The effectiveness of the moratorium will likely be evaluated based on metrics such as the number of fraudulent applications detected, the amount of improper payments prevented, and the overall impact on program integrity.

The agency will also be monitoring the impact of the pause on patient access to essential medical equipment. Stakeholders, including patient advocacy groups and DMEPOS suppliers, will be closely watching to ensure that the moratorium does not create undue hardship for individuals who rely on these devices to maintain their health and quality of life. Ongoing dialogue and collaboration between CMS and the DMEPOS community will be crucial to finding a sustainable solution that balances the need to combat fraud with the imperative to ensure timely and equitable access to care.

Further information regarding the CMS tipline for reporting fraud will be released in the coming weeks. Individuals with information about suspected fraudulent activity are encouraged to submit tips through the designated channels, contributing to the ongoing effort to protect the integrity of the Medicare and Medicaid programs. Patients with concerns about their DME supply should contact their healthcare provider or Medicare directly.